↓ Skip to main content

Dove Medical Press

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population

Overview of attention for article published in Neuropsychiatric Disease and Treatment, February 2019
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

twitter
4 X users
facebook
1 Facebook page

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
55 Mendeley
Title
Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
Published in
Neuropsychiatric Disease and Treatment, February 2019
DOI 10.2147/ndt.s189668
Pubmed ID
Authors

Adam J Savitz, Haiyan Xu, Srihari Gopal, Isaac Nuamah, Paulien Ravenstijn, David Hough, Ludger Hargarter

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 55 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 16 29%
Researcher 7 13%
Student > Master 5 9%
Other 3 5%
Student > Ph. D. Student 3 5%
Other 7 13%
Unknown 14 25%
Readers by discipline Count As %
Medicine and Dentistry 15 27%
Pharmacology, Toxicology and Pharmaceutical Science 5 9%
Psychology 5 9%
Nursing and Health Professions 3 5%
Biochemistry, Genetics and Molecular Biology 3 5%
Other 8 15%
Unknown 16 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 February 2019.
All research outputs
#14,608,799
of 25,385,509 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,304
of 3,131 outputs
Outputs of similar age
#221,877
of 447,265 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#16
of 63 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,131 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 447,265 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 63 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.